Elan's (ELN +3%) board has rejected the sweetened takeover bid from Royalty Pharma, saying it...

|About: Elan Corporation, plc (ELN)|By:, SA News Editor

Elan's (ELN +3%) board has rejected the sweetened takeover bid from Royalty Pharma, saying it "continues to grossly undervalue" the company, with board chairman Robert Ingram adding that it's "no more than an opportunistic attempt to acquire our company at a substantial discount at our shareholders' expense." It urges shareholders to reject the offer, noting also that it's reducing the acceptance threshold to 50% plus one share from 90%.